Supplementary Table 1.
Clinical Characteristics and Comorbidities of COVID-19 IBD Cohort
| Variable | All IBD (n = 118) |
|---|---|
| Age, y, mean (SD) | 42.1 (16) |
| Sex, n (%) | |
| Female | 63 (54) |
| Male | 54 (46) |
| IBD type | |
| Crohn’s disease | 73 (62) |
| Ulcerative colitis | 40 (34) |
| Other colitis | 5 (4.2) |
| Body mass index, kg/m2 average (SD) | 27 (6.8) |
| Comorbidities, n (%) | |
| Obesity | 30 (25) |
| Former smoker | 23 (20) |
| Current smoker | 2 (1.7) |
| Diabetes | 5 (4.3) |
| CAD | 2 (1.7) |
| Heart failure | 1 (0.9) |
| Hypertension | 20 (17) |
| Asthma | 8 (6.9) |
| COPD | 0 (0) |
| Cirrhosis | 1 (0.9) |
| Chronic kidney disease | 1 (0.9 |
| Current medications, n (%) | |
| Any biologic | 65 (55) |
| Anti-TNF | 23 (20) |
| Vedolizumab | 22 (19) |
| Ustekinumab | 20 (17) |
| JAK inhibitors | 6 (5.1) |
| Immunomodulator | 4 (3.4) |
| Steroids | 19 (16) |
| Prednisone | 8 (6.8) |
| Budesonide | 11 (9.3) |
| Mesalamines | |
| Oral | 40 (34) |
| Rectal | 25 (21) |
| Hypertension medications | 17 (15) |
| ACE-ARB medications | 7 (6.0) |
| NSAIDS | 4 (3.4) |
| COVID-19 symptoms, n (%) | |
| Upper respiratory | 97 (87) |
| Gastrointestinal | 43 (39) |
| COVID treatment, n (%) | |
| Steroids | 6 (5.4) |
| Azithromycin | 20 (18) |
| Hydroxychloroquine | 12 (11) |
| Lopinavir/ritonavir | 0 (0) |
| Tocilizumab | 1 (0.9) |
| Remdesivir | 1 (0.9) |
| Other antibiotics | 2 (1.9) |
| COVID outcomes, n (%) | |
| ED visit | 18 (15) |
| Hospitalization | 8 (6.8) |
| Ventilation | 1 (0.9) |
| ICU | 1 (0.9) |
| Death | 0 (0) |
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ED, emergency department; IBD, inflammatory bowel disease; ICU, intensive care unit; NSAIDS, nonsteroidal anti-inflammatory drugs; SD, standard deviation; TNF, tumor necrosis factor.